← All trials
NCT05353257
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2022
- Primary completion
- Dec 30, 2024
- Completion date
- Jun 30, 2026
- First posted
- Apr 29, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 482
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Henlius BiotechLead sponsor
- Jilin Provincial Tumor HospitalOverall official - principal investigator
- Jilin Provincial Tumor HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.